At the archive date, BIOGEN INC. was expected to release its Q3 2026 10-Q filing on October 28, 2026. Last quarter: Biogen reported 2026-Q2 total revenue of $2,736.0 million (+3.4% YoY), driven by the addition of Apellis products and growth in rare disease therapies, though net profitability fell sharply due to acquisition step-up costs and higher operating and IPR&D expenses.
EPS Estimate
$2.07
Revenue Estimate
$2.69B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the BIIB page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
Biogen completed the acquisition of Apellis Pharmaceuticals on May 14, 2026, for $5.1B net of cash acquired (funded via cash and $2.4B in net borrowings), adding $127.8M in specialized immunology product revenue from SYFOVRE and EMPAVELI in 2026-Q2.
Total revenue increased 3.4% YoY to $2,736.0M in 2026-Q2, supported by 10.8% growth in rare disease products ($58.7M increase) and ZURZUVAE sales ($70.8M), which offset a 13.0% ($143.9M) drop in Multiple Sclerosis (MS) product revenue due to generic competition for TECFIDERA.
Total cost and expense increased 36.9% ($702.1M) YoY to $2,602.1M in 2026-Q2, driven by higher cost of sales (+28.4%), R&D (+32.7%), SG&A (+21.6%), and $164.0M in acquired IPR&D/milestone expenses, resulting in a $3.67 (84.8%) drop in diluted EPS.
Revenue
$2.74B
+3.42% YoY
EPS (Diluted)
$0.66
-84.76% YoY
Add BIIB to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.